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Background
Cytotoxic chemotherapy is the standard treatment in
most cancer patients with advanced stage. However,
many patients suffer from severe side effects even if the
anti-cancer treatment is effective. There is no estab-
lished strategy to prevent wide range of side effects of
cytotoxic chemotherapy including appetite loss, myelo-
suppression, and acute renal injury.
Atrial natriuretic peptide (ANP) has been used clinically
for the treatment with heart failure in Japan, and exhibits
a wide range of biological activities including cardiovascu-
lar and renal protection through binding the guanylate
cyclase-A (GC-A) receptor. Recent studies also reported
that exogenous ANP pre-treatment reduced renal fibrosis
in acute renal injury model. However, there is no evidence
about ANP protection against tissue injury by cisplatin,
which is a representative cytotoxic agent for most cancer
treatment. This study was designed to examine whether
ANP pre-treatment attenuates tissue injury including
acute renal failure induced by cisplatin.
Materials and methods
We used C57/B6 mice which were pre-treated with saline
or ANP (subcutaneously via osmotic-pump, 0.5 μg/kg/
min) and administered intravenously a dose of 12 mg/kg
cisplatin as the experimental acute renal failure mode.
ANP infusion was started one day before the administra-
tion of cisplatin. This dose does not change blood pressure
and heart rate in mice.
Results
Mice with cisplatin showed weight loss, myelosuppres-
sion (decrease of white blood cell and platelet), and
increased inflammatory cytokine mRNA levels in the kid-
ney compared to the control mice. ANP-pretreated mice
showed the attenuation of weight loss (19.9 ± 0.5 vs.
15.9 ± 0.6 g, P < 0.01), myelosuppression (white blood
cell; 2700 ± 632 vs. 1300 ± 141 cell/µl, P < 0.01 , platelet;
64.8 ± 15.5 vs. 39.6 ± 5.7 ×104 cell/µl, P < 0.01), and
increased tumor-necrosis factor alpha (TNFa), interleu-
kin-6 (IL-6), and monocyte chemotactic protein-1 (MCP-
1) mRNA levels in the kidney compared to the control
mice with cisplatin.
Conclusion
We found that ANP reduced the great variety of side
effects induced by cisplatin. These protective effects on tis-
sue injury induced by cisplatin was considered through
anti-inflammatory effects of ANP. Our data provide novel
insights into the prophylactic therapy for various side
effects induced by cytotoxic chemotherapy in many cancer
patients.
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